AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21914410
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment only (group B)
Trial: 16842145
Drug: New pharmacological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New pharmacological approaches to improve vascular homeostasis, specifically targeting oxidative stress reduction or antioxidant defense augmentation.
Trial: 15160263
Drug: Perospirone 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perospirone 4 mg
Trial: 15160263
Drug: Paroxetine 20
RxNorm normalized name: PARoxetine 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine 20 mg plus perospirone 4 mg
Trial: 9369917
Drug: Systemic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic chemotherapy for chemo-sensitive tumors
Trial: 9369917
Drug: Instillation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instillation of drugs like doxycycline, OK-432, or bleomycin
Trial: 3512070
Drug: Maintenance chemotherapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance chemotherapy plus immunotherapy with Nocardia rubra cell-wall skeleton (N-CWS) and irradiated allogeneic AML cells
Trial: 30524633
Drug: Combination Therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination Therapy (CT) with lumbopelvic stability training (LPST)
Trial: 30524633
Drug: Standard Massage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Massage Therapy (MT)
Trial: 28324268
Drug: Ridaforolimus 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ridaforolimus 30 mg daily for 5 of 7 days plus dalotuzumab 10 mg/kg/week
Trial: 28324268
Drug: Any ridaforolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any ridaforolimus dose
Trial: 28324268
Drug: Ridaforolimus 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ridaforolimus 20 mg qd x 5 days/week
Trial: 28324268
Drug: Ridaforolimus 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ridaforolimus 10 mg qd x 5 days/week
Trial: 20462580
Drug: Weekly telephone
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly telephone support
Trial: 16299259
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen (HBO(2)) over 20 treatments
Trial: 15270890
Drug: Topical paricalcitol
RxNorm normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical paricalcitol ointment (15 microg g(‐1))
Trial: 12067146
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy (HBO2T)
Trial: 9359979
Drug: moclobemide (MOC;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: moclobemide (MOC; 400 mg daily)
Trial: 9359979
Drug: nortriptyline (NT;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nortriptyline (NT; 75 mg daily)
Trial: 3535008
Drug: Ketanserin, 40‐160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin, 40‐160 mg daily
Trial: 31106659
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acid group: 2 omega-3 fatty acid capsules (330 mg each) daily + vitamin D3 placebo weekly
Trial: 31106659
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D group: 50,000 IU vitamin D3 soft gel weekly + 2 omega-3 fatty acid placebo capsules daily
Trial: 31106659
Drug: Cosupplementation group:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cosupplementation group: 50,000 IU vitamin D3 soft gel weekly + 2 omega-3 fatty acids capsules daily for 8 weeks
Trial: 31106659
Drug: Control group:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group: vitamin D3 placebo weekly + omega-3 fatty acid placebo capsules daily
Trial: 27751554
Drug: MIS plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MIS plus alteplase (0.3 mg or 1.0 mg every 8 hours for up to nine doses)
Trial: 20374035
Drug: Rhodiola algida
RxNorm normalized name: RHODIOLA ROSEA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhodiola algida mixture consumed for 14 consecutive days after each cycle of chemotherapy
Trial: 18389895
Drug: Comparator ritonavir‐boosted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator ritonavir‐boosted protease inhibitor (CPI/r)
Trial: 16288157
Drug: Exercise program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise program (45-50 minutes, twice a week for 8 weeks)
Trial: 11414432
Drug: Artesunate 200
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Artesunate 200 mg once daily for 3 days
Trial: 11414432
Drug: Artesunate 200
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Artesunate 200 mg together with mefloquine 10 mg/kg on the first 2 days and artesunate 200 mg together with mefloquine 5 mg/kg on the third day
Trial: 11414432
Drug: Artesunate 200
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Artesunate 200 mg together with azithromycin 50 mg once daily for 3 days
Trial: 8439637
Drug: Early nizatidine
RxNorm normalized name: Nizatidine
DrugBank: Nizatidine (DB00585)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early nizatidine (300 mg) with early supper (18.00 hours)
Trial: 8439637
Drug: Late nizatidine
RxNorm normalized name: Nizatidine
DrugBank: Nizatidine (DB00585)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Late nizatidine (300 mg) with late supper (21.00 hours)
Trial: 8439637
Drug: Early nizatidine
RxNorm normalized name: Nizatidine
DrugBank: Nizatidine (DB00585)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early nizatidine (300 mg) with late supper (21.00 hours)
Trial: 29143803
Drug: High-protein diet
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-protein diet (125 g protein/day) using novel functional foods
Trial: 29143803
Drug: Conventional diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional diet (80 g protein/day)
Trial: 16412769
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist plus recombinant luteinizing hormone
Trial: 16412769
Drug: Standard GnRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard GnRH agonist flare-up protocol
Trial: 11417474
Drug: Daunorubicin continuous
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daunorubicin continuous infusion (CI) 60 mg/m2 days 2-4
Trial: 11417474
Drug: Bolus daunorubicin
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bolus daunorubicin (30-min infusion) 60 mg/m2
Trial: 11417474
Drug: Daunorubicin continuous
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daunorubicin continuous infusion (CI)
Trial: 11417474
Drug: Bolus daunorubicin
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bolus daunorubicin (30-min infusion)
Trial: 9562303
Drug: Anti-NF antibodies
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-NF antibodies in ALS patients
Trial: 8179465
Drug: Desipramine (long-term
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desipramine (long-term treatment for 28 days)
Trial: 8179465
Drug: Desipramine (long-term
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desipramine (long-term treatment)
Trial: 3068741
Drug: Nifedipine, 10
RxNorm normalized name: Nifedipine, 10 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine, 10 mg three times a day
Trial: 21803405
Drug: 80 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 μg delprostenate
Trial: 21803405
Drug: 160 μg
RxNorm normalized name: immunoglobulin G, human 160 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 μg delprostenate
Trial: 16513871
Drug: Risperidone (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (2.5 mg)
Trial: 9307345
Drug: Sertraline hydrochloride
RxNorm normalized name: sertraline hydrochloride
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sertraline hydrochloride (50-150 mg daily)
Trial: 334132
Drug: Acetazolamide 63
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetazolamide 63 mg
Trial: 24028643
Drug: Acetazolamide 125
RxNorm normalized name: acetazolamide 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide 125 mg
Trial: 1544778
Drug: Acetazolamide 500
RxNorm normalized name: acetazolamide 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide 500 mg
Trial: 334132
Drug: Acetazolamide 0
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetazolamide 0 mg (control)
Trial: 27417302
Drug: Education and
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Free and Clear]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Education and acceptance and commitment therapy intervention (n=39)
Trial: 18251162
Drug: Vitamin K2
RxNorm normalized name: Vitamin K2
DrugBank: Menaquinone 6 (DB14936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K2 (VK2), 45 mg orally every day after therapy for HCC
Trial: 18251162
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no VK2 treatment)
Trial: 15771794
Drug: Paraplatin dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paraplatin dosage calculated according to body surface
Trial: 15771794
Drug: Paraplatin dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paraplatin dosage calculated according to area under the curve (AUC)
Trial: 9883316
Drug: LPS stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPS stimulation (5 micrograms/ml)
Trial: 9883316
Drug: NDV stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NDV stimulation (640 HU/ml)
Trial: 2048708
Drug: Group II
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group II (tourniquet applied after midazolam injection)
Trial: 2048708
Drug: Group I
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group I (tourniquet applied before midazolam injection)
Trial: 7044525
Drug: Tamoxifen (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (10 mg p.o. twice daily)
Trial: 7044525
Drug: Aminoglutethimide (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminoglutethimide (250 mg p.o. 4 times daily) with hydrocortisone (20 mg twice daily)
Trial: 25394826
Drug: Inhaled oxygen
RxNorm normalized name: oxygen Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled oxygen fraction (FiO₂) 1.0, 0.21, 0.15, and 0.10 with body positions (upright, supine, and 45° head down)
Trial: 21490143
Drug: ZnSuppl group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZnSuppl group (6 mg Zn added to the supplement dose)
Trial: 21490143
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (30 g dry weight of iron-fortified cereal porridge and a liquid multivitamin supplement without zinc)
Trial: 21490143
Drug: ZnFort group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZnFort group (zinc added to provide 6 mg Zn per 25 g dry weight of porridge and multivitamin without zinc)
Trial: 19622294
Drug: Celecoxib plus
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib plus surgery (200 mg twice daily for six days before surgery)
Trial: 6373303
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy for non-responders
Trial: 23253701
Drug: Standard-intensity warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-intensity warfarin (INR 2.1 to 2.5)
Trial: 23253701
Drug: Low-intensity warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity warfarin (INR 1.6 to 2.0)
Trial: 23253701
Drug: Aspirin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (200 mg per day)
Trial: 23253701
Drug: Standard-intensity warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-intensity warfarin
Trial: 10369553
Drug: Zemaphyte (traditional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zemaphyte (traditional Chinese herbal medicine)
Trial: 2669155
Drug: Hydrochlorothiazide (HCTZ)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCTZ) 50 mg/day
Trial: 1930859
Drug: Nifedipine (NIF)
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine (NIF) 90 mg/day
Trial: 3911962
Drug: Suprofen suppositories
RxNorm normalized name: Suprofen
DrugBank: Suprofen (DB00870)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Suprofen suppositories
Trial: 24397109
Drug: Granulocyte-colony stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Granulocyte-colony stimulating factor (GCSF); dosage and duration not specified.
Trial: 16804018
Drug: Fermented papaya
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fermented papaya preparation 9 g/day
Trial: 12654667
Drug: 1263W94 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1263W94 (50 to 1,600 mg)
Trial: 12654667
Drug: 1263W94 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1263W94 (100 to 1,600 mg)
Trial: 8634929
Drug: Heater probe
RxNorm normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heater probe thermocoagulation therapy and cimetidine 300mg i.v. q6h
Trial: 8634929
Drug: Omeprazole 40mg
RxNorm normalized name: OMEPRAZOLE 40MG CAP,SA
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole 40mg intravenous bolus initially followed by 40mg i.v. qd
Trial: 8634929
Drug: Omeprazole 40mg
RxNorm normalized name: OMEPRAZOLE 40MG CAP,SA
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole 40mg intravenous bolus initially followed by 40mg i.v. q12h
Trial: 1473431
Drug: Piroxicam-beta-cyclodextrin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam-beta-cyclodextrin (20 mg/day for 14 days)
Trial: 1473431
Drug: Standard Piroxicam
RxNorm normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard Piroxicam (20 mg/day for 14 days)
Trial: 1473431
Drug: Indomethacin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (100 mg/day for 14 days)
Trial: 24995756
Drug: Nicotine replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine replacement pharmacotherapy (6-week regimen)
Trial: 24995756
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no nicotine replacement therapy)
Trial: 20141732
Drug: Integrated traditional
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated traditional Chinese medicine therapy and chemotherapy
Trial: 17394179
Drug: anti-tumor necrosis
RxNorm normalized name: G 1 (anti-tumor agent)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-tumor necrosis factor alpha (anti-TNFalpha) therapy
Trial: 15826418
Drug: Autologous blood
RxNorm normalized name: Banked autologous blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous blood re-infusion units
Trial: 7784683
Drug: Continuous intrathecal
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intrathecal anesthesia with 10 mg hyperbaric bupivacaine (Group 1)
Trial: 7784683
Drug: Continuous intrathecal
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intrathecal anesthesia with 10 mg hyperbaric bupivacaine and 25 mcg fentanyl (Group 2)
Trial: 7784683
Drug: Single intrathecal
RxNorm normalized name: Intrathecal Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intrathecal dose of 15 mg hyperbaric bupivacaine (Group 3)
Trial: 2113756
Drug: Selegiline (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selegiline (30 mg/day)
Trial: 474476
Drug: 11.5 mg
RxNorm normalized name: pectin 11.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 11.5 mg zinc daily
Trial: 474476
Drug: 14.7 mg
RxNorm normalized name: arginine 14.7 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14.7 mg zinc daily
Trial: 31041683
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine therapy alone (ET)
Trial: 31041683
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus endocrine therapy (ET + C)
Trial: 23359344
Drug: Tabalumab 30
RxNorm normalized name: Tabalumab
DrugBank: Tabalumab (DB11657)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tabalumab 30 mg
Trial: 23359344
Drug: Tabalumab 60
RxNorm normalized name: Tabalumab
DrugBank: Tabalumab (DB11657)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tabalumab 60 mg
Trial: 23359344
Drug: Tabalumab 160
RxNorm normalized name: Tabalumab
DrugBank: Tabalumab (DB11657)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tabalumab 160 mg
Trial: 23359344
Drug: Tabalumab (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tabalumab (all doses combined)
Trial: 20888709
Drug: RT +
RxNorm normalized name: CVS Yogurt + Fiber Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT + cisplatin (20 mg/m² weekly)
Trial: 16551158
Drug: Youth‐Nominated Support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Youth‐Nominated Support Team‐Version 1 (YST‐1) plus treatment-as-usual
Trial: 16551158
Drug: Treatment-as-usual only
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual only
Trial: 8006643
Drug: Interferon-alpha (IFN)
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha (IFN) therapy
Trial: 9106647
Drug: Oral etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral etoposide (100 mg given twice daily for 5 days)
Trial: 9106647
Drug: Intravenous chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous chemotherapy (cisplatin and etoposide alternating with cyclophosphamide, doxorubicin, and vincristine)
Trial: 8459986
Drug: Ondansetron plus
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron plus dexamethasone (0.15 mg/kg i.v. x 3 and 20 mg i.v.)
Trial: 8459986
Drug: Metoclopramide plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide plus dexamethasone (3 mg/kg i.v. x 2 and 20 mg i.v.)
Trial: 24754070
Drug: Intravenous Idrinol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Idrinol 1000 mg/day for 10-14 days (Group 1)
Trial: 24754070
Drug: Basic therapy
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic therapy of coronary heart disease (Group 2)
Trial: 28865098
Drug: Acotiamide 300
RxNorm normalized name: acetiamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acotiamide 300 mg/day + rabeprazole 10 mg/day
Trial: 27982344
Drug: Late open
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late open lung strategy (L-OLS)
Trial: 23688323
Drug: Dupilumab (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab (300 mg) administered subcutaneously once weekly for 12 weeks
Trial: 23688323
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered subcutaneously once weekly for 12 weeks
Trial: 20090438
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of intraperitoneal lidocaine
Trial: 18171451
Drug: 50% dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50% dose + placebo
Trial: 18171451
Drug: 50% dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50% dose
Trial: 18171451
Drug: Baseline (100%)
RxNorm normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline (100%) dose
Trial: 10908209
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus coumarins
Trial: 8757358
Drug: Once-daily dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily dosing of gentamicin or tobramycin (4 mg/kg IV)
Trial: 8757358
Drug: Pharmacokinetic dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacokinetic dosing (initial dose of 2 mg/kg IV every 12 hours)